Japan Lifeline Co., Ltd. has received regulatory approval for its proprietary radiofrequency transseptal wire, XEROstar. The device is designed to streamline the transseptal puncture process during catheter ablation procedures for atrial fibrillation by enabling a "zero exchange workflow." XEROstar, which features a flexible wire shape and a half-pigtail tip to reduce procedural risks and improve efficiency, is scheduled for full market release as early as March 2026. The company expects the financial impact of this approval on its consolidated results for the fiscal year ending March 2026 to be negligible.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JLL - Japan Lifeline Co. Ltd. published the original content used to generate this news brief on January 13, 2026, and is solely responsible for the information contained therein.